Trials / Active Not Recruiting
Active Not RecruitingNCT06364163
Effect of Herring Oil Concentrate on LDL Cholesterol Concentration in Adults
A Study on the Effect of Consuming a Herring Oil Concentrate on LDL Cholesterol Concentration in Adults With Overweight or Obesity
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- University of Bergen · Academic / Other
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
High cholesterol concentration is a major risk factor for cardiovascular disease (CVD), and consumption of fish has been associated with a lower CVD risk in several studies. The beneficial health effects of consuming fish have traditionally been ascribed to the long-chain PUFA (LC-PUFA) EPA (C20:5n-3) and DHA (C22:6n-3), although consumption of fish oils or concentrates with high EPA and DHA contents does not affect the cholesterol concentration in humans and lowers the cholesterol concentration in rats and mice only when given in very high doses. Fish oils contain a plethora of fatty acids besides EPA and DHA, and in recent years, increased focus has been on the long-chain MUFA (LC-MUFA) cetoleic acid (C22:1n-11). Cetoleic acid is found in high amounts in oils from certain fish species such as herring, which has relatively low contents of both EPA and DHA. The investigators have recently summarised and meta-analysed the available literature that investigates the effects of diets containing fish oils or fish oil concentrates that have a high content of cetoleic acid but low or no content of EPA and DHA on cholesterol concentration in rodents, showing that cetoleic acid-rich fish oils and concentrates prevent high cholesterol concentration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Herring oil concentrate | Capsules containing herring oil concentrate, taken daily for 8 weeks. |
| DIETARY_SUPPLEMENT | Control | Capsules containing control oil, taken daily for 8 weeks. |
Timeline
- Start date
- 2024-08-12
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2024-04-15
- Last updated
- 2025-10-02
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT06364163. Inclusion in this directory is not an endorsement.